Drug Type Mesenchymal stem cell therapy |
Synonyms Thrombin-preconditioned allogeneic Wharton's Jelly-derived mesenchymal stem cells |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cerebral Intraventricular Hemorrhage | Phase 1 | KR | 11 May 2023 |